The US Food and Drug Administration has approved Eli Lilly’s once-weekly basal insulin for people with type 2 diabetes.
The product, called Onswik, is designed to reduce the number of insulin injections required each week.
The approval could provide another treatment option for patients who require basal insulin.
The FDA decision follows clinical testing of the medication.
Eli Lilly is preparing the product for the US market.
Doctors will determine whether the treatment is appropriate for individual patients.
The company says the weekly treatment could make insulin administration more convenient.
